Palonosetron Generic Name & Formulations
Palonosetron (as HCl) 0.075mg/1.5mL, 0.25mg/5mL; IV inj; contains mannitol.
Selective 5-HT3 receptor antagonist.
Prevention of acute and delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of highly emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.
Palonosetron Dosage and Administration
≥17yrs: give 30mins prior to chemotherapy. 0.25mg IV as a single-dose over 30secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10secs.
<1 month: not established. 1 month–<17yrs: give 30mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15mins; max 1.5mg/dose.
Palonosetron Boxed Warnings
Discontinue and treat if hypersensitivity reactions occur; do not reinitiate. Monitor for serotonin syndrome; discontinue and treat if occurs. Pregnancy. Nursing mothers.
Increased risk of serotonin syndrome when concomitant with other serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue).
Palonosetron Adverse Reactions
Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.
Palonosetron Clinical Trials
Formerly known under the brand name Aloxi.
Palonosetron Patient Counseling